# Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

> **NCT00924001** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Melanoma
- Malignant Melanoma
- Melanoma, Experimental

## Interventions

- **DRUG:** DMF5 Melanoma Reactive TIL
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT00924001
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** study was stopped due to low accrual
- **Last updated:** 2012-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924001, "Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00924001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*